Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Fisetin to Reduce Senescence and Mobility Impairment in PAD

A legfontosabb adatok

Ki végzi
Northwestern University
Hol
Chicago (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
34 fő, tervezett
Kezdés
2024. szept. 30.
Várható befejezés
2027. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Fisetin
  • Placebo
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

The trial is looking for people aged 50 and older with peripheral artery disease (PAD), a narrowing of leg arteries that limits walking. It tests whether fisetin improves walking compared with placebo.

Életkor
50 years and older
Nem
All sexes. Women can join only after menopause (no period in the past 12 months).
A betegség stádiuma
PAD shown by an ankle brachial index (ABI) of 0.90 or less, or vascular lab or angiography evidence (at least 70% narrowing of a leg artery), or an ABI above 0.90 and up to 1.00 with a 20% or greater drop after a heel-rise test. Six-minute walk distance must be between 500 feet and 1600 feet.
Korábbi kezelés
No fisetin in the previous three months. No supervised treadmill exercise program in the previous three months. No major surgery, heart or leg artery procedure in the previous three months.
A részvétel fő kizáró okai
  • Leg amputation, severe loss of blood flow to the leg (critical limb ischemia), or a foot ulcer on the bottom of the foot
  • Using a wheelchair or walker, or walking limited by something other than PAD
  • Major illness such as lung disease needing oxygen, Parkinson's disease, or cancer treated in the past two years
  • Living with HIV, or active hepatitis B or C without a low viral load
  • Severe kidney weakness (eGFR less than 25 ml/min/1.73 m2), HemoglobinA1C above 10, or BMI above 43
A regiszter összes feltétele (31)A regiszter feltételeinek elrejtése

Ki vehet részt

  • First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:
  • An ankle brachial index (ABI) less than or equal to 0.90 at baseline
  • Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities
  • An ABI of greater than 0.90 and less than or equal to 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included

Ki nem vehet részt

  • Planned major surgery, coronary or leg revascularization during the next five months
  • Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  • Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  • Currently taking fisetin or has taken fisetin in previous three months
  • Current participation in or completion of a clinical trial intervention in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a clinical trial (other than stem cell or gene therapy), participants will be eligible after the final study intervention as long as at least three months have passed since the final intervention of the trial.]
  • Participation in a supervised treadmill exercise program in previous three months
  • People taking warfarin and other sensitive substrates of CYP2C9, CYP2C19, or CYP1A2 that have a narrow therapeutic window will be excluded, unless the drug can be held for at least two days prior to the first day of each study drug administration and can continue to be held for ten hours after the second dose of study drug administration for each of the two days of study drug dosing
  • Current foot ulcer on bottom of foot
  • Failure to successfully complete the study run-in
  • Allergy to fisetin
  • Visual impairment that limits walking ability
  • HemoglobinA1C great than 10 as a marker of poor diabetes control
  • People who are Human Immunodeficiency Virus positive (HIV+) and people with active hepatitis B or active hepatitis C infections who do not have a low viral load
  • People with a bilirubin above 2.2 mg/dl, with serum aspartate transaminase (AST) or alanine aminotransferase (ALT) more than four times the upper limit of normal
  • Hemoglobin less than 7.0 g/dl, white blood count less than 2,000/mm3, white blood count greater than 20,000/mm3, platelet count less than 40,000/uL
  • Estimated glomerular filtration rate (eGFR) less than 25 ml/min/1.73 m2
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant. In some instances, patients whose medications or laboratory data meet exclusion criteria may participate at the Principal Investigator's discretion
  • Above- or below-knee amputation
  • Critical limb ischemia defined as an ABI less than 0.40 with signs or symptoms of critical limb ischemia
  • Wheelchair confinement or requiring a walker to ambulate
  • Walking is limited by a symptom other than PAD
  • Mini-Mental Status Examination (MMSE) score less than 23
  • Non-English speaking
  • Six-minute walk distance of less than 500 feet or greater than1600 feet
  • Participants may be excluded if they are unwilling to undergo a fat biopsy. However, if investigators find recruitment significantly slows due to this exclusion, participants may still be able to participate in the trial if they refuse the fat biopsy
  • Women who are not menopausal will be excluded. Menopause is defined as absence of a menstrual period in the past 12 months
  • Body mass index (BMI) great than 43

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Northwestern University Feinberg School of MedicineChicago, Egyesült ÁllamokContact: Kathryn J DomanchukRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.

A vizsgálat 2 csoportja

  • FisetinA vizsgált kezelés

    Sharp Clinical Services will provide fisetin (100 mg capsules). Randomized participants will receive fisetin 20 mgs/kg once daily for two days, followed by 12 days without therapy. Fisetin will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

  • PlaceboPlacebo, összehasonlításként

    Sharp Clinical Services will provide placebo (100 mg capsules). Randomized participants will receive placebo 20 mgs/kg once daily for two days, followed by 12 days without therapy. Placebo will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 1 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 17.
Kérdések a feltételekről
Forrás: NCT06399809: ki vehet részt
A regiszteradat frissítve
2026. november 16.